【摘要】 目的观察钙通道阻滞剂维拉帕米对免疫抑制剂他克莫司(FK506)血浓度及临床的影响。方法将患者分为直接治疗组(10例)和FK506切换治疗组(11例),检测服用FK506的肾移植患者口服钙拮抗剂维拉帕米前后自身FK506血浓度变化、量化关系及不良反应。结果直接用药组患者维拉帕米能提高肾移植患者FK506血浓度的53.3%,减少术后FK506服用量的33.3%,切换治疗组患者服用维拉帕米后FK506血浓度也有明显增高,两组肝肾功能都有明显改善。结论维拉帕米提高肾移植患者FK506血浓度、减少术后FK506的服用量,改善肝毒性,具有较大的临床应用价值及社会经济效益。更多还原

【Abstract】 Objective To investigate the clinical impact of verapamil and its effect on tacrolimus(FK506)blood concentration.Method The21patients underwent kidney transplantation were divided into direct treatment group(10cases)and FK506changed treatment group(11cases).The changes of blood concentration of FK506were detected and compared before and after taking verapamil,and their dosage relation and adverse reaction were also observed.Result After taking verapamil the FK506blood concentration was raised53.3%,the treatment dosage of FK506was reduced33.3%and verapamil reduced toxicity of FK506on kidney and liver.The functions of liver and kidney were improved significantly.Conclusion After kidney transplantation,the FK506blood concentration in patients taking FK506with verapamil raises significantly,the treatment dosage of FK506get reduced,there is very big value and significance in clinical practice and social economy effectiveness.[更多还原